HUP9904023A2 - Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban - Google Patents

Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban

Info

Publication number
HUP9904023A2
HUP9904023A2 HU9904023A HUP9904023A HUP9904023A2 HU P9904023 A2 HUP9904023 A2 HU P9904023A2 HU 9904023 A HU9904023 A HU 9904023A HU P9904023 A HUP9904023 A HU P9904023A HU P9904023 A2 HUP9904023 A2 HU P9904023A2
Authority
HU
Hungary
Prior art keywords
type
diabetes
insulin resistance
treating insulin
leptin antagonists
Prior art date
Application number
HU9904023A
Other languages
English (en)
Inventor
Johann Ertl
Günter Müller
Gerald Preibisch
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of HUP9904023A2 publication Critical patent/HUP9904023A2/hu
Publication of HUP9904023A3 publication Critical patent/HUP9904023A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A találmány II. típűsú cűkőrbaj kezelésére alkalmas gyógyászatikészítményekre vőnatkőzik, amelyek leptin antagőnistákat tartalmaznak.Az egyik leptin antagőnista rágcsáló leptin fragmentűmőkőn alapszik éstartalmazza a 116-167. vagy 116-166. aminősavakat. A találmányeljárásőkat is tartalmaz II. típűsú cűkőrbaj kezelésére. ŕ
HU9904023A 1996-09-20 1997-09-15 Use of leptin antagonists for treating insulin resistance in type ii diabetes HUP9904023A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19638487 1996-09-20
PCT/EP1997/005035 WO1998012224A1 (en) 1996-09-20 1997-09-15 Use of leptin antagonists for treating insulin resistance in type ii diabetes

Publications (2)

Publication Number Publication Date
HUP9904023A2 true HUP9904023A2 (hu) 2000-03-28
HUP9904023A3 HUP9904023A3 (en) 2002-01-28

Family

ID=7806282

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904023A HUP9904023A3 (en) 1996-09-20 1997-09-15 Use of leptin antagonists for treating insulin resistance in type ii diabetes

Country Status (18)

Country Link
US (1) US6399745B1 (hu)
EP (1) EP0956302A1 (hu)
JP (1) JP2001500869A (hu)
KR (1) KR20010029537A (hu)
CN (1) CN1230966A (hu)
AR (1) AR008444A1 (hu)
AU (1) AU735178B2 (hu)
BR (1) BR9711513A (hu)
CA (1) CA2266585A1 (hu)
CZ (1) CZ90999A3 (hu)
HU (1) HUP9904023A3 (hu)
ID (1) ID21861A (hu)
IL (1) IL129057A0 (hu)
NO (1) NO991186L (hu)
PL (1) PL332458A1 (hu)
RU (1) RU2201249C2 (hu)
WO (1) WO1998012224A1 (hu)
ZA (1) ZA978455B (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756617B2 (en) 1998-07-28 2003-01-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
AU782230B2 (en) 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
EP1283878B1 (en) 2000-05-22 2005-07-27 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Receptor-based interaction trap
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN103897066A (zh) 2004-02-11 2014-07-02 安米林药品有限责任公司 具有可选择特性的杂合多肽
US7407929B2 (en) * 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
KR101123549B1 (ko) 2004-11-01 2012-04-18 아밀린 파마슈티칼스, 인크. 비만 및 관련 장애의 치료
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2006053883A1 (en) 2004-11-18 2006-05-26 Vib Vzw Fibronectin iii domain as leptin receptor antagonists
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
EP2392595A1 (en) 2005-02-11 2011-12-07 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EA200870365A1 (ru) * 2006-03-23 2009-02-27 Амилин Фармасьютикалз, Инк. Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
US20100323955A1 (en) * 2007-11-14 2010-12-23 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8778890B2 (en) 2009-03-31 2014-07-15 Temple University—Of the Commonwealth System of Higher Education Leptin antagonist and methods of use
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
JP6040464B2 (ja) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
HUE042196T2 (hu) 2013-11-26 2019-06-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829708B (zh) 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
EA201990720A1 (ru) 2016-09-12 2019-08-30 Эгерион Фармасьютикалс, Инк. Способы детекции нейтрализующих антител к лептину
EP3675961A1 (en) * 2017-08-31 2020-07-08 University Of Dundee Leptin peptides and their use for treating neurological disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) * 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) * 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
KR19990028388A (ko) * 1995-06-30 1999-04-15 피터 지. 스트링거 당뇨병 치료 방법
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US5922678A (en) * 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes

Also Published As

Publication number Publication date
PL332458A1 (en) 1999-09-13
ZA978455B (en) 1998-03-20
NO991186D0 (no) 1999-03-11
WO1998012224A1 (en) 1998-03-26
ID21861A (id) 1999-08-05
IL129057A0 (en) 2000-02-17
NO991186L (no) 1999-03-11
US6399745B1 (en) 2002-06-04
BR9711513A (pt) 1999-08-24
AR008444A1 (es) 2000-01-19
JP2001500869A (ja) 2001-01-23
CA2266585A1 (en) 1998-03-26
HUP9904023A3 (en) 2002-01-28
RU2201249C2 (ru) 2003-03-27
AU4458697A (en) 1998-04-14
EP0956302A1 (en) 1999-11-17
KR20010029537A (ko) 2001-04-06
CN1230966A (zh) 1999-10-06
AU735178B2 (en) 2001-07-05
CZ90999A3 (cs) 1999-06-16

Similar Documents

Publication Publication Date Title
HUP9904023A2 (hu) Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
EP0908186A3 (en) Method for treating pain
ATE241351T1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
BR9607647A (pt) Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
MX9200709A (es) Activacion mejorada de proteinas recombinadas. activacion mejorada de proteinas recombinadas.
GR1000172B (el) Βελτιωσεις εις η εν σχεσει προς τις σωματοστατινες.
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
DE29602789U1 (de) Liege, Decke o.dgl. zur therapeutischen Behandlung von Lebewesen
WO1994017792A3 (en) Compositions and methods for transdermal drug delivery
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
ES2057572T3 (es) Agentes de reconocimiento.
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
EP0908180A3 (en) Use of phenyl oxazole or phenyl thiazole derivatives for treating pain
HUP9903688A2 (hu) Olanzapin alkalmazása az autizmus kezelésére szolgáló gyógyszerkészítmény előállítására
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
IS5324A (is) (S) 2-Metýlamínó-2-fenýl-n-bútýl 3,4,5-trímetoxý-bensóat, notkun þess til meðferðar á langvinnum sársauka
DK0811068T3 (da) Humane DNase I varianter
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine